There have also been developed cell-free tumour vaccines containing α-fetoprotein-enriched DC-derived exosomes, which stimulate immune cells to produce IFN-γ and IL-2 and reduce the expression of TGFβ and IL-10 at the site of the tumour, thus, inducing antigen-specific response to cancer cells. This evidence concerns the gene IL2 and neoplasm.